Curasight and Curium have agreed to develop and commercialise the former’s uTRACE positron emission tomography (PET) imaging technology for use in prostate cancer.

Both entities have signed an exclusive global licence and collaboration agreement in this regard.

Under the deal, Curasight will be responsible for the development of the uTRACEtechnology for use in prostate cancer with the aim of obtaining regulatory approval in the European Union (EU) and the US.

Curium will be tasked with the commercial production of uTRACE, as well as the commercialisation of the product across the world.

Curasight will receive up to $70m after the achievement of development and commercial milestones related to the product.

Furthermore, the company will be entitled to receive double-digit percentage royalties on product sales in major markets upon successful commercialisation.

Curasight’s objective is to establish uTRACE as a pioneering PET tracer, offering an alternative or supplement to conventional biopsies for use in assessing patients undergoing active surveillance for prostate cancer.

Curasight CEO Ulrich Krasilnikoff said: “Our collaboration pairs Curasight’s strengths in the development of uTRACE and Curium’s proven expertise, capacity, and global track record in the manufacturing and commercialisation of radiopharmaceuticals.

“This partnership supports further development of our diagnostic platform, bringing us closer to fulfilling our ambition of helping a large number of prostate cancer patients.”

The uTRACEplatform forms part of Curasights uPAR theranostic solution, which is a combination of targeted radionuclide therapy and non-invasive PET imaging.

The theranostic solution includes the uTREATtargeted treatment technology and the uTRACEdiagnostic technology.

The main objective of the uTRACE platform is to improve the diagnosis of certain types of cancer including prostate cancer. It enables the provision of personalised treatment solutions for each patient.

Multiple Phase II clinical trials have validated the efficacy of this technology.